Moderna (NASDAQ:MRNA) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

Moderna Stock Performance

Moderna stock traded down $1.19 during midday trading on Tuesday, reaching $27.16. The stock had a trading volume of 11,618,643 shares, compared to its average volume of 6,890,839. The stock has a market capitalization of $10.50 billion, a P/E ratio of -2.93 and a beta of 1.86. The firm's fifty day simple moving average is $34.60 and its 200-day simple moving average is $43.84. Moderna, Inc. has a 1-year low of $26.80 and a 1-year high of $170.47.

Remove Ads

Institutional Investors Weigh In On Moderna

Institutional investors have recently made changes to their positions in the company. Wilmington Savings Fund Society FSB lifted its holdings in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in shares of Moderna during the fourth quarter worth $37,000. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock worth $37,000 after buying an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Moderna in the fourth quarter valued at about $41,000. Finally, Itau Unibanco Holding S.A. increased its position in Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the period. Institutional investors own 75.33% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently commented on MRNA shares. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. JPMorgan Chase & Co. cut their price target on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a research report on Friday, March 21st. The Goldman Sachs Group cut Moderna from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and lowered their target price for the company from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $40.00 price target on shares of Moderna in a research report on Tuesday, February 18th. Four equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $59.00.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.